{"prompt": "['Novartis', 'Confidential', 'Page 25', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '8. Use of tetracycline (e.g. doxycycline) or macrolide antibiotics specifically within the 8', 'weeks prior to the start of the Run-in period due to the influence they have on Nasal', 'Polyps.', '9. Any contra-indications to inhaled or nasal steroids e.g. narrow angle glaucoma, or any', 'other as decided by the Investigator.', '10. Pregnant or nursing (lactating) women', '11. Women of child-bearing potential, defined as all women physiologically capable of', 'becoming pregnant, unless they are using basic methods of contraception during dosing of', 'investigational drug. Basic contraception methods include:', 'Total abstinence (when this is in line with the preferred and usual lifestyle of the', 'subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation', 'methods) and withdrawal are not acceptable methods of contraception', 'Female sterilization (have had surgical bilateral oophorectomy with or without', 'hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking', 'investigational drug. In case of oophorectomy alone, only when the reproductive', 'status of the woman has been confirmed by follow-up hormone level assessment', 'Male sterilization (at least 6 months prior to screening). For female subjects on the', 'study, the vasectomized male partner should be the sole partner for that subject', 'Barrier methods of contraception: Condom or Occlusive cap (diaphragm or', 'cervical/vault caps). For UK: with spermicidal foam/gel/film/cream/vaginal', 'suppository', 'Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of', 'contraception or other forms of hormonal contraception that have comparable efficacy', '(failure rate <1%), for example hormone vaginal ring or transdermal hormone', 'contraception or placement of an intrauterine device (IUD) or intrauterine system', '(IUS)', 'In case of use of oral contraception women should have been stable on the same pill for a', 'minimum of 3 months before taking investigational drug.', 'Women are considered post-menopausal and not of child bearing potential if they have', 'had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile', '(e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral', 'oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least', 'six weeks ago. In the case of oophorectomy alone, only when the reproductive status of', 'the woman has been confirmed by follow up hormone level assessment is she considered', 'not of child bearing potential.', 'If local regulations deviate from the contraception methods listed above to prevent', 'pregnancy, then local regulations apply and will be described in the informed consent', 'form.', '12. Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days until', 'the expected pharmacodynamic effect has returned to baseline, whichever is longer.', '13. History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar', 'chemical classes.']['Novartis', 'Confidential', 'Page 26', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '14. History of malignancy of any organ system (other than localized basal cell carcinoma of', 'the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless', 'of whether there is evidence of local recurrence or metastases.', '15. Patients who are unable to follow instructions to complete the study, either because of', 'mental or physical conditions.', '16. Patients with a terminal disease, or conditions that may impede the timely completion of', 'the study as decided by the investigator.', '17. Patients with a diagnosis of Cystic Fibrosis', '18. History of nasal surgery (including polypectomy) within 6 months prior to screening.', '19. History of sinus or nasal surgery modifying the structure of the nose such that assessment', 'of NPS via nasal endoscopy is not possible.', '20. Patients with a diagnosis of ciliary dyskinesia', '21. Patients with allergic fungal sinusitis as diagnosed from previous surgery or from CT', 'scan.', '22. Patients with ACQ-5 > 1.5 at Screening', '23. Uncontrolled epistaxis requiring surgical or procedural intervention, including nasal', 'packing, within 2 months of screening', '24. Concomitant conditions that interfere with evaluation of the primary endpoint:', 'Marked nasal septal deviation occluding one or both nostrils', 'Ongoing rhinitis medicamentosa', 'Acute sinusitis, nasal infection or upper respiratory tract infection during run-in', 'period.', '25. Initiation of or change in immunotherapy or aspirin desensitization for allergies within', '3', 'months prior to Screening or during the Run-in period.', '26. Patients receiving any medications in the classes listed in Table 6-2 should be excluded', 'unless they meet the criteria as specified in Table 6-2.', '27. Patients on >20 mg of simvastatin, > 40 mg of atorvastatin, >40 mg of pravastatin, or >2', 'mg of pitavastatin 7 days prior to run-in visit. Statin doses less than or equal to these doses', 'as well as other statins will be permitted during the study', '28. Patients on any statin therapy with a CK level >2 X ULN at Screening Visit', '29. Patients receiving any medications in the classes listed in Table 6-1 should be excluded', 'unless the medication has been stabilized for the specified period and the stated conditions', 'have been met', '30. Patients receiving any medications or other agents known to prolong the QT interval.', '31. Patients with any chronic condition of the respiratory tract which in the opinion of the', 'investigator may interfere with study evaluation or optimal participation in the study.', '32. Patients with a history of chronic lung disease other than asthma, including (but not', 'limited to) chronic obstructive pulmonary disease, bronchiectasis, (non-clinically', 'significant bronchiectasis may be allowed provided recent [within 3 months prior to', 'Screening Visit] CT scan proof is available), sarcoidosis, interstitial lung disease, and', 'tuberculosis.']\n\n###\n\n", "completion": "END"}